Skip to main content
Glenmark Pharmaceuticals ltd logo

Glenmark Pharmaceuticals ltd — Investor Relations & Filings

Ticker · GLENMARK ISIN · INE935A01035 LEI · 335800WKECZXIIT9GK20 BSE.NS Manufacturing
Open in API
Filings indexed 1,051 across all filing types
Latest filing 2018-11-05 Call Transcript
Country IN India
Listing BSE.NS GLENMARK

About Glenmark Pharmaceuticals ltd

https://glenmarkpharma.com/

Glenmark Pharmaceuticals Ltd. is a research-driven global organization focused on the development, manufacturing, and marketing of generic, specialty, and over-the-counter medicines. The company maintains a specialized focus on therapeutic areas including dermatology, respiratory health, and oncology. It operates a robust research and development pipeline featuring New Chemical Entities (NCEs) and New Biological Entities (NBEs), supported by multiple global R&D centers. Its commercial footprint extends across North America, Europe, and emerging markets. The company is distinguished by its expertise in complex generics and its integrated approach to drug discovery and formulation development. Glenmark utilizes a network of advanced manufacturing facilities to deliver high-quality healthcare solutions globally, emphasizing innovation and accessibility in its product portfolio.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 90% confidence The document is an invitation to an earnings call for Glenmark's Q2 FY 2018-19 results. It includes the date, time, dial-in numbers, and contact information for clarifications. There is no financial data or detailed transcript content, only an announcement of the call event. Therefore, this document is best classified as a Call Transcript (CT) category, specifically an invitation to a conference call related to earnings results.
2018-11-05 English
Trading Window
Regulatory Filings Classification · 100% confidence The document text is extremely short (69 characters) and contains no substantive content, only a placeholder for an omitted picture. There is no financial data, report title, regulatory references, or any descriptive text. Given the lack of content, this cannot be classified as any substantive report or announcement. It fits best as a Regulatory Filing (RNS) which is the fallback category for miscellaneous filings without clear classification.
2018-11-02 English
Board Meeting — Financial Results
Regulatory Filings Classification · 90% confidence The document text is extremely short (69 characters) and contains no substantive content, only a placeholder for an omitted picture. There is no financial data, report title, regulatory references, or any other information to classify it as a specific report type. Given the lack of content, the document cannot be classified as a report or announcement. According to the rules, such minimal content defaults to Regulatory Filings (RNS) as a fallback category.
2018-11-02 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a new product (Nourkrin®) by Glenmark Pharmaceuticals in Russia. It is addressed to stock exchanges and includes a media release for immediate dissemination. There are no financial statements, regulatory filings, or detailed financial data. The content is promotional and informational about a product launch, not a financial report or regulatory filing. It is not an announcement of voting results, management changes, or capital changes. The document is a typical corporate press release for a product launch, which fits best under the category of Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2018-11-01 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release dated October 30, 2018, announcing that Glenmark Pharmaceuticals has received ANDA approval from the U.S. FDA for a specific topical oil product. It is addressed to stock exchanges and includes a media release for immediate distribution. The content focuses on a regulatory approval event and product pipeline update, not on financial results, management changes, or detailed financial data. The document length is 3404 characters, which is relatively short and typical for a press release. There is no indication of it being an annual report, earnings release, or any detailed financial or governance report. It is an announcement of a regulatory approval and product update, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2018-10-30 English
Press Release
Capital/Financing Update Classification · 95% confidence The document is a press release announcing that Glenmark Pharmaceuticals has received ANDA approval from the U.S. FDA for a specific pharmaceutical product. It is addressed to stock exchanges and includes a media release for immediate dissemination. There are no financial statements, detailed financial performance data, or regulatory filings such as annual or quarterly reports. The document is a corporate announcement about a regulatory approval related to product development and market authorization. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings for financial compliance. The best fitting category is Capital/Financing Update (CAP) because it relates to a significant corporate development impacting the company's product portfolio and potential revenue streams, which is typical for capital or financing updates in pharmaceutical companies.
2018-10-26 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.